What is ViOptix?
ViOptix operates at the intersection of advanced engineering and clinical medicine, specializing in the measurement of tissue oxygen saturation. The company's core product portfolio, which includes the T.Ox, T.Ox Remote, and Intra.Ox systems, provides surgeons with real-time, actionable insights that are particularly vital in complex procedures such as breast reconstruction. By delivering high-fidelity data, ViOptix empowers medical professionals to make informed decisions, thereby reducing complications and improving recovery trajectories. Their market position is defined by a commitment to clinical evidence and the integration of innovative monitoring tools into standard hospital workflows, effectively bridging the gap between diagnostic technology and bedside patient management.
How much funding has ViOptix raised?
ViOptix has raised a total of $24.4M across 3 funding rounds:
Series C
$9.2M
Series D
$12.2M
Series E
$3M
Series C (2004): $9.2M with participation from Morningside Group, IN-vivo Ventures, Trident Investments, and MDS Capital
Series D (2008): $12.2M led by Morningside Venture Investments
Series E (2010): $3M, investors not publicly disclosed
Key Investors in ViOptix
Morningside Venture Investments
Founded in 1986 by the Chan family, this firm focuses on private equity and venture capital, leveraging deep industry knowledge and an entrepreneurial approach to support high-growth companies.
MDS Capital
A specialized venture capital and private equity firm based in Canada, focusing on investments within the healthcare and life sciences sectors.
IN-vivo Ventures
A venture capital firm dedicated to supporting early-stage and growth-oriented companies within the life sciences and medical technology industries.
What's next for ViOptix?
With the recent influx of capital, ViOptix is well-positioned to scale its operational footprint and accelerate the adoption of its tissue oximetry platforms across global clinical settings. The company's strategic roadmap likely involves expanding its research and development efforts to enhance the sensitivity and versatility of its existing product line. Furthermore, as the healthcare industry increasingly prioritizes data-driven surgical interventions, ViOptix is poised to capitalize on the growing demand for non-invasive monitoring solutions. By maintaining its focus on clinical excellence and technological innovation, the firm is set to solidify its influence in the medical device market, potentially exploring new therapeutic applications for its core oxygen saturation technology.
See full ViOptix company page
